Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.20.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Total revenue $ 4,141 $ 7,008
Operating expenses:    
Research and development 20,631 8,454
General and administrative 5,647 4,935
Total operating expenses 26,278 13,389
Loss from operations 22,137 6,381
Interest and other income, net 472 510
Interest and other expense, net (348) (293)
Change in fair value of warrant liabilities 0 (4)
Loss before provision for income taxes 22,013 6,168
Provision for income taxes 5 0
Net loss 22,018 6,168
Net loss attributable to common shareholders $ 22,018 $ 6,168
Net loss per share attributable to common shareholders:    
Basic and diluted $ 0.48 $ 0.17
Weighted average number of shares used in net loss per share calculations:    
Basic and diluted 45,649,065 36,738,993
Research And Development Revenue | Other    
Total revenue $ 1,467 $ 0
Research And Development Revenue | Related Party    
Total revenue 333 6,413
Grant    
Total revenue $ 2,341 $ 595